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Fungal infections have become a major public health problem, growing in number and
severity in recent decades due to an increase of immunocompromised patients. The use
of therapeutic agents available to treat these fungal infections is limited by their toxicity,
low bioavailability, antifungal resistance, and high cost of treatment. Thus, it becomes
extremely important to search for new therapeutic options. The use of polymeric
systems as drug carriers has emerged as a promising alternative to conventional
formulations for antifungals. Alginate is a natural polymer that has been explored in
the last decade for development of drug delivery systems due to its non-toxicity,
biodegradability, biocompatibility, low cost, mucoadhesive, and non-immunogenic
properties. Several antifungal agents have been incorporated in alginate-based delivery
systems, including micro and nanoparticles, with great success, displaying promising
in vitro and in vivo results for antifungal activities, reduction in the toxicity and the
total drug dose used in the treatment, and improved bioavailability. This review aims
at discussing the potential use and benefits of alginate-based nanocarriers and other
delivery systems containing antifungal agents in the therapy of fungal infections.
Keywords: antifungal, alginate, drug delivery systems, nanoparticles, amphotericin B
INTRODUCTION
Fungal infections have become a major public health problem and are growing in number and
severity over the past three decades. The development of new medical treatments, including
therapy with immunosuppressive agents and chemotherapy of cancer, led to a dramatic increase in
the number of immunocompromised individuals who are vulnerable to infections which otherwise
would have been easily resolved (Karkowska-Kuleta et al., 2009). More than 1.7 billion people
worldwide are estimated to suffer from fungal diseases, ranging from superficial to invasive
infections (Brown et al., 2012), and some of these infections cause more deaths per year than
tuberculosis or malaria (Gaffi – Global Action Fund for Fungal Infections, 2016). However, deaths
resulting from invasive or chronic fungal infections are often overlooked, and most public health
agencies present little or no mycological surveillance programs (Brown et al., 2012). Preventive
measures, premature diagnosis, and the availability of appropriate antifungal treatment could
reduce death rates by fungal infections.
The current antifungal therapy is based on three major chemical classes: echinocandins,
polyenes, and azoles. Echinocandins are β(1,3)-glucan synthase inhibitors, disrupting the synthesis
of the cell wall β(1,3)-D-glucan polymer. Polyenes and azoles alter cytoplasm membrane
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permeability; polyenes bind irreversibly to ergosterol whilst
azoles inhibit ergosterol biosynthesis specifically inhibiting
cytochrome P450 dependent enzyme lanosterol 14-α-deme-
thylase. Other antifungals as allylamines and pyrimidine analogs
find use against a few fungal infections, mainly to treat cutaneous
mycosis (Ostrosky-Zeichner et al., 2010). It is important to
emphasize that most antifungal compounds are approved
for treatment of superficial mycoses, especially in topical
formulations (Denning and Bromley, 2015). In contrast, the
clinical repertoire for treatment of invasive fungal infections
(IFIs) is much smaller, with only nine approved compounds:
amphotericin B, fluconazole, voriconazole, itraconazole,
posaconazole, caspofungin, anidulafungin, micafungin, and
flucytosine (Denning and Bromley, 2015).
However, the use of these compounds for IFIs is complicated
by their poor solubility and bioavailability due to problems in
drug absorption and distribution. The situation is aggravated by
difficulties to deliver the drug to its target, which leads to an
increased incidence of adverse effects resultant from the lack
of drug selectivity, which compromise efficacy and safety. An
example is the polyene amphotericin B; the drug displays a
broad spectrum of action and fungicidal effect, but the significant
number of serious adverse effects (which include nephrotoxicity)
limits its wider therapeutic use (Hamill, 2013). Triazole agents
also exhibit adverse effects associated mainly to hepatic disorders,
and their interaction with other drugs have been described
due to their ability to modulate the activity of cytochrome
P450 enzymes and the hepatic oxidative metabolism of many
drugs (Peyton et al., 2015). Even the newest antifungal agents,
the echinocandins, present low oral bioavailability and cause
gastrointestinal effects after intravenous administration (Chen
et al., 2011).
This scenario becomes more complicated if we take into
consideration the challenges related to the development of new
antifungal agents. The fact that fungi are evolutionarily close
to their human host impairs the discovery of new compounds
with selective action (Seneviratne and Rosa, 2016). These factors
associated with increases in antifungal resistance (Pfaller, 2012),
emergence of uncommon fungi (Davoudi et al., 2015; Roilides,
2016), and high mortality rates (Brown et al., 2012; Gaffi – Global
Action Fund for Fungal Infections, 2016) have led the scientific
community to search for other ways to improve drug targeting
and efficacy while reducing adverse effects.
In this context, drug delivery systems emerge as promising
alternatives to improve therapy and overcome the above-
mentioned limitations (Figure 1A). They have been
demonstrated to reduce toxicity caused by conventional
drug treatments, improve drug efficacy and bioavailability,
reduce dose and administration frequency, and might allow oral
administration of compounds with unfavorable pharmacokinetic
characteristics, formerly used in topical and/or intravenous
forms (Kumar et al., 2013). Various nanocarriers, such as
dendrimers, polymers, liposomes, nanoemulsions, and micelles
have been investigated for drug delivery (Jeevanandam et al.,
2016).
Amphotericin B lipid formulations are examples of the
successful application of drug nanocarriers to improve thera-
peutic outcomes. Three lipid formulations of amphotericin B
are available for medical use: liposomal (L-AMB); colloidal
dispersion (ABCD); and a lipid complex (ABLC). All were
developed to reduce nephrotoxicity without compromising the
antifungal efficacy (Falci et al., 2015). The L-AMB formulation
(Ambisome R©) incorporates the drug into liposomes, lipid vesicles
of 55–75 nm in diameter composed of soy lecithin, cholesterol,
and distearoylphosphatidylglycerol. In the ABCD formulation
(Amphocil R©), amphotericin B is co-incorporated with cholesterol
sulfate in microdiscs of an average diameter of 122 nm. The
ABLC formulation (Abelcet R©) is a macromolecular complex
of amphotericin B with dimyristoylphosphatidylcholine and
dimyristoylphosphatidylglycerol forming ribbon-like particles
ranging in length from 1,600 to 6,000 nm (Tiphine et al., 1999;
Martinez, 2006; Voltan et al., 2016).
Amphotericin B association with lipids improves drug
dissolution, facilitates parenteral infusion, protects the drug
from destruction by enzymatic degradation and/or host immune
factor inactivation and changes the pharmacokinetic profile of
amphotericin B by slow drug release resulting in the protection
of potentially vulnerable tissues (most importantly, the kidneys)
(Hamill, 2013). In a review, the lipid-based compounds were
associated with less risk of changes in renal function, while
the risk of a doubling in serum creatinine from baseline
was 58% less likely with the lipid based formulations (Barrett
et al., 2003). Moreover, the slow and continuous release of
amphotericin B from lipid formulations allow the administration
of higher doses and longer treatment (Hamill, 2013). However,
although lipid-based amphotericin B formulations have shown
equivalent efficacy and reduced toxicity compared with the
conventional amphotericin B formulation, they are often
reserved as a secondary treatment option, presumably because of
the differences in costs (Wade et al., 2013).
Various other antifungal agents could benefit from the ability
of delivery systems to modify pharmacokinetics and reduce
adverse effects. In fact, several studies have been conducted
on incorporation of other antifungal agents in various types of
delivery systems in the past years, suggesting a demand for novel
cost-effective and safe delivery platforms. In this review, we will
discuss non-lipid drug carriers for antifungal agents, emphasizing
the relevance of alginate-based carriers as an interesting approach
for delivery of antifungal agents.
POLYMERIC SYSTEMS
Among the many types of modified release systems developed,
polymer-based systems have attracted attention as they offer
significant advantages over other carrier platforms primarily
due to the tremendous versatility of polymer matrices, which
allows for tailoring of the carrier properties to meet the
specific intended need. Other advantages of polymeric
systems include ease of production, high encapsulation
efficiency of the molecule of interest, protection of the drug
against physicochemical degradation, flexibility of their
physicochemical properties (such as size, surface charge,
and hydrophobicity), slow or fast polymer degradation and
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FIGURE 1 | Schematic representation showing some of the benefits of using carriers in drug formulations (A) and advantages of alginate natural
polymer (B).
stimuli-responsive polymer erosion for temporal control over
the release of drugs (Van Vlerken et al., 2007; Voltan et al.,
2016).
Bulk gels, films, micro and nanocarriers have been prepared
using natural polymers, such as alginate (Liakos et al., 2013;
Elsayed et al., 2015), chitosan (Al-Kassas et al., 2016; Islam
and Ferro, 2016), gelatin (Mahor et al., 2016), dextran (Gallovic
et al., 2016), or synthetic polymers, such as polylactic acid (PLA)
(Tyler et al., 2016), poly(lactide-co-glycolide) (PLGA) (Han et al.,
2016; Thomas et al., 2016) and others. Natural polysaccharides
are advantageous compared to the synthetic polymers due to
their abundance in nature, low processing cost, biocompatibility,
biodegradability, water solubility, bioactivity, and environmental
safety (Sundar et al., 2010; Debele et al., 2016). Among the
biopolymers used, alginate represents an excellent alternative for
obtainment of drug carriers and is the main focus of this review.
ALGINATE
Alginate is a generic name assigned to a series of natural
unbranched polyanionic polysaccharides of β-D-mannuronic
acid (M) and α-L-guluronic acid (G) (Figure 2) repeating
units linked by a 1→4 linkage and displaying chain
homosequences of MMM and GGG, interdispersed with
MGM heterosequences (Lee and Mooney, 2012; Sosnik, 2014).
Molecular weights in the range of 32–400 kg/mol together
with different relative G/M compositions and variations
in the proportion and chain arrangements of M and G
blocks might be found depending on type of seaweed from
which alginate was extracted (Sosnik, 2014; Cardoso et al.,
2016).
This polysaccharide is frequently obtained from brown
seaweeds, including Laminaria hyperborea, Laminaria digitata,
FIGURE 2 | Molecular structures of α-L-guluronic acid (G) and
β-D-mannuronic acid (M) from alginate polymer.
Laminaria japonica, Ascophyllum nodosum, and Macrocystis
pyrifera (Lee and Mooney, 2012). Alginate extraction is
conducted by treatment with aqueous alkali solutions, typically
sodium hydroxide, in which the natural alginate in various
salt forms is converted into water-soluble sodium alginate; the
extract is filtered, and either sodium or calcium chloride is
added to the filtrate in order to precipitate alginate. After further
purification and conversion, water-soluble sodium alginate
powder is produced (Qin, 2008; Lee and Mooney, 2012). On
a dry weight basis, the alginate contents are 22–30% for
A. nodosum, 25–44% for L. digitata, and 17–33 and 25–30%,
respectively, for the fronds and stems of L. hyperborea (Qin,
2008).
Another alginate source is bacteria from the Azotobacter
and Pseudomonas species. The alginate biosynthesis pathway in
bacteria can be divided into four different stages: (i) synthesis
of precursor substrate, (ii) polymerization and cytoplasmic
membrane transfer, (iii) periplasmic transfer and modification,
and (iv) export through the outer membrane. However, even
under optimized fermentation conditions, production yields are
quite low (around 4 g/l) (Remminghorst and Rehm, 2006), and
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the process is not considered economically viable for commercial
applications (Goh et al., 2012).
Alginate has important characteristics that make it one
of the most used polymers for drug delivery application: it
is non-toxic, biocompatible, non-immunogenic, biodegradable,
mucoadhesive, readily available and has low cost (Figure 1B)
(Hosseini et al., 2013; Paques et al., 2014). Various modified
drug delivery systems can be obtained using alginate, such
as hydrogels (polymeric networks with three-dimensional
configuration capable of imbibing high amounts of water or
biological fluid), microparticles (diameter from 1 to 200 µm)
and nanoparticles (diameter from 10 to 1000 nm) (Hamidi et al.,
2008; Sosnik, 2014). Depending on the desired application and
formulation characteristics, different techniques can be used to
produce the carriers. The ionotropic gelation is the most common
method used to obtain alginate-based nano and microparticles,
beads and hydrogels, among other systems, due to its simplicity
and non-toxic procedure.
In this process, alginate is crosslinked in aqueous solutions
ionotropically by a mechanism whereby pendant carboxylic acid
moieties of G units chelate Ca2+ or other divalent cations
(e.g., Sr2+, Ba2+) to generate 3D networks that allow the
incorporation of compounds (Tønnesen and Karlsen, 2002;
Sosnik, 2014). This gelation is known as the “egg box model”
and has been demonstrated to result from specific and strong
interactions between calcium ions and blocks of guluronic acid
residues (Braccini and Pérez, 2001). Biomolecules and other
drugs can be loaded under mild conditions and retained in the
3D structure (Paques et al., 2014; Lopes et al., 2016). Ionotropic
gelation can be divided into external and internal gelation. The
main difference between these methods is the type of calcium
salt used and consequently the gelling kinetics (Draget et al.,
2005).
In the external gelation method, which is also referred to
as the “diffusion method” particles are produced by dropping
a drug-loaded alginate solution into the aqueous solution
of a soluble salt of calcium, such as calcium chloride. The
internal gelation method, also referred to as “internal setting,”
is characterized by the release of calcium ions in a controlled
manner from an insoluble calcium source, such as calcium
carbonate, within the alginate solution. Controlled release of
calcium is usually obtained by a change in pH, by a limited
solubility of the calcium salt source, and/or by the presence of
chelating agents (Draget et al., 2005; Paques et al., 2014; Lopes
et al., 2016).
Micro and nanoparticles of alginate are usually obtained
using emulsification (W/O or O/W) followed by external
or internal gelation (Hosseini et al., 2013; Paques et al.,
2013; Song et al., 2013). Emulsions are basically obtained
by dispersing a fluid into another immiscible fluid and are
produced by fragmenting, through various processes, one phase
into another, and leading to a dispersion of droplets in a
continuous phase. The recombination of the freshly formed
droplets may be partially suppressed by the addition of
surfactants that locate at the droplet interface reducing the
interfacial tension (Bibette and Leal-Calderon, 1996; Pillai et al.,
1999).
ALGINATE-BASED DELIVERY SYSTEMS
FOR ANTIFUNGAL DRUGS
Several types of alginate-based delivery systems for antifungal
agents have been studied in the last few years, such as
nanoparticles and microparticles, beads, hydrogels, tablets, and
films. In the next sections, alginate–based carriers for two classes
of antifungal agents will be addressed: azoles and polyenes
(Table 1).
Azoles
Azoles inhibit the fungal cytochrome P450 (CYP) enzyme
14-α-sterol-demethylase, which is involved in ergosterol
biosynthesis, a major sterol component of fungal cytoplasmic
membranes (Kathiravan et al., 2012). Therapeutic use of azoles
displays two main problems. The first one is their ability
to interact with mammalian P450 isozymes, affecting the
metabolism of other drugs that serve as substrates of these
enzymes, which may result in significant drug interactions
including reduced efficacy or increased incidence of adverse
effects. The second drawback relates to the low aqueous solubility
of several azoles: miconazole, ketoconazole, itraconazole,
and posaconazole are all slightly water-soluble (<1 µg/ml)
or insoluble at neutral pH (Yang et al., 2008). Low aqueous
solubility is known to severely limit azole bioavailability after
oral administration and its therapeutic effectiveness. The low
concentration of the drug at the infection site may also induce
antifungal resistance to some less susceptible species (Yang
et al., 2008). The first limitation is more easily addressed
by local drug delivery to the site of infection, which can be
prolonged/controlled using alginate-based carriers. Systemic
administration of alginate carriers can overcome the second, as
they have been demonstrated to improve the bioavailability of
antifungal imidazoles and triazoles in various studies, improving
efficacy while potentially reducing the frequency of drug
administration.
Imidazoles
Econazole and clotrimazole have been mainly used topically
due to the low absorption after oral administration (Fromtling,
1988). To improve the oral bioavailability, Pandey et al.
(2005) encapsulated these antifungals separately in alginate
nanoparticles. When free drug was administered, it was detected
in the plasma of animals for up to 3–4 h. In contrast, after
administration of the alginate nanoparticles, econazole, and
clotrimazole could be detected for longer periods of time (5–
6 days). In addition, the drugs were detected in the lung,
liver, and spleen up to 8 days following administration of
the nanoparticles, while free antifungals were cleared within
12 h. Thus, reduced frequency of antifungal administration was
proposed as a potential advantage of the alginate nanoparticles
containing econazole or clotrimazole.
Ahmad et al. (2007) evaluated the chemotherapeutic
potential of alginate nanoparticles encapsulating econazole
and antitubercular drugs (ATDs) against murine tuberculosis.
Azole drugs have proven their antimycobacterial potential
under in vitro, ex vivo, and in vivo conditions against murine
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TABLE 1 | Alginate-based drug delivery systems for antifungal agents azoles and polyenes.
Antifungal Carrier Therapeutic goal Experimental model Reference
Clotrimazole Alginate nanoparticles Improve bioavailability of the drug In vivo (mice) Pandey et al., 2005
Films of sodium alginate, hydroxyl
propylcellulose and propylene glycol
Treatment of vaginal candidiasis In vitro Mishra et al., 2016
Econazole Alginate nanoparticles Improve bioavailability of the drug In vivo (mice) Pandey et al., 2005
Alginate nanoparticles Chemotherapeutic potential against
murine tuberculosis
In vivo (mice) Ahmad et al., 2007
Miconazole Tablets of alginate Evaluation of the buccal bioadhesive
properties of slow-release tablets
containing miconazole
In vitro and in vivo
(human voluntary)
Mohammed and Khedr,
2003
Fluconazole Films of sodium alginate and polyvinyl
alcohol
Overcome the problems of high drug
dose requirement and toxicity
In vitro and ex vivo Patel et al., 2015
Ethyl cellulose microspheres with
internal phase of alginate
Antifungal activity against Candida
albicans
In vitro Maiti et al., 2009
Alginate mucoadhesive films and disks Topical treatment of oral candidiasis In vitro and in vivo
(human voluntary)
Yehia et al., 2008, 2009
Voriconazole Pluronic and sodium alginate gels Ocular drug delivery against C. albicans
and Aspergillus fumigatus
In vitro Pawar and Edgar, 2012
Amphotericin B Sodium alginate nanospheres Treatment of systemic candidiasis In vitro and in vivo
(mice)
Sangeetha et al., 2007
Sodium alginate-glycol chitosan
stearate nanoparticles
for better chemotherapy of visceral
leishmaniasis
In vitro and in vivo
(hamster)
Gupta et al., 2015
Alginate films with starch Pickering
emulsions
Treatment of oral candidiasis In vitro Cossu et al., 2015
Alginate-capped amphotericin B lipid Treatment of visceral leishmaniasis In vitro Singodia et al., 2011
Nystatin Alginate beads, micro- and
nanoparticles incorporated in
toothpaste
Increase the effectiveness of the
nystatin in the treatment of oral
candidiasis
In vitro Reis et al., 2015
Alginate microspheres and alginate
hydrogel
Treatment of oral candidiasis In vitro and in vivo (pigs) Martín et al., 2015
Alginate microparticles, chitosan and
poloxamer 407 coated alginate
microparticles
Treatment of Candida vaginitis In vitro and ex vivo Martín-Villena et al.,
2013
tuberculosis caused by susceptible, resistant, and latent bacilli
(Ahmad et al., 2006). They observed that co-encapsulation
of these drugs in alginate nanoparticles reduced the dosing
frequency of econazole and ATDs by 15-fold, suggesting the
advantage of their encapsulation for sustained release of these
drugs (Ahmad et al., 2007).
Other studies demonstrated the applicability of alginate
to obtain mucoadhesive carriers for treatment of mucosal
candidiasis. Mishra et al. (2016) investigated mucoadhesive
films of clotrimazole for vaginal administration, a patient-
convenient alternative for treatment of vaginal candidiasis.
Conventional vaginal dosage forms, such as creams, foams,
jellies have short residence time at the site of application,
resulting in reduced therapeutic effect. Vaginal films possess
several advantages including the ease of storage and handling,
no need of an applicator, and better drug stability (Hussain
and Ahsan, 2005; Mishra et al., 2016). The optimized film
provided higher drug release than the marketed product Candid-
V6 R© vaginal tablet (70% drug release in 1 h and 83% drug
release in 6 h while marketed product showed 14% drug
release in 1 h and 41% drug release in 6 h). In addition, the
films maintained in vitro antifungal activity without inhibiting
Lactobacillus growth (Mishra et al., 2016). Mohammed and
Khedr (2003) obtained slow-release buccal bioadhesive alginate
tablets of miconazole, and demonstrated that these tablets
markedly prolonged the duration of antifungal activity of the
drug in the saliva of human volunteers for more than 8 h
compared with the commercial miconazole gel (Daktaren oral
gel), improving patient convenience.
Triazoles
Maiti et al. (2009) prepared ethyl cellulose microspheres with
high entrapment levels of fluconazole by alginate facilitated
water-in-oil-in-water (w/o/w) emulsion solvent evaporation
technique. The drug entrapment efficiency (%) in ethyl cellulose
microspheres, prepared by conventional w/o/w emulsion solvent
evaporation technique, was found to be 10.93 ± 1.23, while the
addition of 2% (w/v) sodium alginate in the internal aqueous
phase of the multiple emulsion improved the efficiency of drug
entrapment to 80% (Maiti et al., 2009), most likely due to an
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increase in the viscosity of the internal phase (Gainza et al.,
2013). In addition, in vitro antifungal activity of fluconazole
incorporated in ethyl cellulose-alginate microspheres against
Candida albicans (MIC ranges from 1.29 to 5.69 µg/ml) were
comparable to the MIC values of free fluconazole (0.12 to
>64 µg/ml) (Maiti et al., 2009). These studies suggested that
the use of aqueous sodium alginate solution as an internal phase
in conventional double emulsion solvent evaporation technique
may be an alternative approach for the successful incorporation
of slightly water soluble drugs in microspheres obtained with
ethyl cellulose and other synthetic polymers (Maiti et al., 2009;
Gainza et al., 2013).
Mucoadhesive disks and films (Yehia et al., 2008, 2009)
containing a small dose of fluconazole were developed for
topical treatment of oral candidiasis to ensure satisfactory
drug levels in the mouth for prolonged time periods, reducing
systemic adverse effects and the possibility of drug–drug
interaction. Compared to other polymers (hydroxypropyl methyl
cellulose, hydroxyethyl cellulose, chitosan, eudragit), the alginate-
based disks containing fluconazole were considered the best
formulation in terms of adhesion characteristics, residence times
and release rates both in in vitro assays and in vivo using the oral
mucosa of human volunteers (Yehia et al., 2009). The alginate
disks containing fluconazole presented swelling and adhesion
properties, increased in vivo residence time and prolonged drug
release over approximately 5 h (Yehia et al., 2008). Recently, Patel
et al. (2015) developed bioadhesive films of fluconazole to provide
localized drug delivery exclusively at the site of infection, thereby
reducing its total dose and hence, dose-related toxicity. The time
necessary for complete erosion or detachment of the film was
over 5 h in an ex vivo model of rat skin surface using a modified IP
(Indian Pharmacopeia) disintegration apparatus; and the in vitro
assays demonstrated a controlled release of the fluconazole up to
8 h using a diffusion cell method (Patel et al., 2015).
Pawar et al. (2013) evaluated the use of a pluronic/alginate-
based gel for ophthalmic delivery of voriconazole. All batches
of formulations were mucoadhesive and displayed a loading
efficiency between 95 and 100%. Importantly, the antifungal
efficiency of the formulation against C. albicans and Aspergillus
fumigatus in vitro confirmed that the designed formulation has
prolonged effect and retained its antifungal properties against
fungal infection. The local voriconazole bioavailability obtained
with alginate-based gel ranged from 19.74 to 30.82% in 4 h
(Pawar et al., 2013) and it was considered an important advantage
to conventional systems, such as eye drops, suspensions, and
ointments that result in less than 5% of administered drug
entering the eye (Gaudana et al., 2009).
Polyenes
Polyene antibiotics form a complex with ergosterol and disrupt
the fungal plasma membrane, increasing membrane permeability
and leakage of the cytoplasmic contents, which results in the
ultimate death of the fungal cell (Kathiravan et al., 2012). Polyene
macrolides are rather toxic, causing serious side effects, such
as renal failure, hypokalemia, and thrombophlebitis, especially
upon intravenous administration. Besides that, these drugs are
poorly soluble in water, and can easily form aggregates of micelles
in aqueous media. This feature is apparently responsible for
the difficulties encountered during administration of polyene
macrolides including poor absorption after oral administration
and poor distribution of the antibiotics in organs and tissues
(Zotchev, 2003).
Amphotericin B alginate films containing starch Pickering
emulsion were demonstrated to be a good alternative for
treatment of mucosa candidiasis. In vitro results demonstrated
efficacy of the emulsions dispersed in alginate films against
C. albicans at concentrations above 5 µg/mL (Cossu et al., 2015).
The inhibitory effect of amphotericin B in the microbiological
assay showed that the addition of 100 U/mL α-amylase resulted
in an enhanced effect on C. albicans due to the increased
bioavailability of amphotericin B released from the emulsions.
This result demonstrated that the release of amphotericin B from
starch Pickering emulsions in alginate films could be controlled
by α-amylase in the system, an interesting feature to provide
release of hydrophobic antifungal, such as amphotericin B (Cossu
et al., 2015).
Alginate nanospheres containing amphotericin B for
treatment of systemic candidiasis in a murine model displayed
higher antifungal efficacy in comparison to the conventional
formulation of amphotericin B (Sangeetha et al., 2007). In the
study, amphotericin B-containing nanospheres administered
intravenously for 7 days led to a mice survival rate of 80%
(compared to 60% for free drug) as well as 10-fold lower fungal
load in the affected organs (liver and lungs) compared with the
free drug (Sangeetha et al., 2007). The authors suggested that
alginate nanospheres containing amphotericin B might improve
biodistribution, enhancing drug localization in the liver and
lungs while reducing it in the kidneys. As a result, a reduction
in total dose as well as dose-related systemic adverse effects
mainly in the kidneys was observed (Sangeetha et al., 2007).
Gupta et al. (2015) produced amphotericin B-loaded alginate
glycol chitosan stearate nanoparticles that presented efficacy
in a visceral leishmaniasis hamster model after intraperitoneal
administration. Drug encapsulation in the nanoparticles
modified its tissue distribution, with higher drug concentrations
being localized in Leishmania infected organs (i.e., spleen and
liver) and lower concentrations in the kidneys, reducing toxicity
compared to the free drug (Gupta et al., 2015).
Another study used amphotericin B in an alginate-capped
lipid nanocarrier (Alg-Lip-nano) for leishmaniasis treatment
(Singodia et al., 2011). In vitro results demonstrated that the
percentage of parasite inhibition (intramacrophagic amastigotes)
of Alg-Lip-nano (58%) was significantly higher compared to
Lip-nano without alginate (48%) (p ≤ 0.05). This supports
the authors hypothesis that alginate coating over lipid particles
activates macrophages to release pro-inflammatory cytokines,
which synergistically act with amphotericin B and can potentially
increase the cure rate in visceral leishmaniasis (Singodia et al.,
2011).
Some work has also been carried out with the polyene
agent nystatin. This compound is recommended only for topical
administration due to its high toxicity. Martín-Villena et al.
(2013) obtained alginate microparticles containing nystatin
through the emulsification/internal gelation method with an
Frontiers in Microbiology | www.frontiersin.org 6 January 2017 | Volume 8 | Article 97
fmicb-08-00097 January 25, 2017 Time: 18:0 # 7
Spadari et al. Alginate-Based Carriers for Antifungals
TABLE 2 | Examples of alginate-based delivery systems for non-conventional antifungals.
Types of materials incorporated Carrier Reference
Essential oils Turmeric chitosan-alginate nanocapsules Lertsutthiwong and
Rojsitthisak, 2011
Turmeric Alginate nanocapsules Lertsutthiwong et al., 2008
Satureja hortensi Alginate microparticles Hosseini et al., 2013
Elicriso italic, chamomile blue, cinnamon, lavender,
tea tree, peppermint, eucalyptus, lemongrass, and
lemon
Alginate films Liakos et al., 2014
Clove, thyme, and cinnamon Alginate microspheres Soliman et al., 2013
Anise Alginate gel Gafit˛anu et al., 2016
Antiseptics Chlorhexidine diacetate Alginate and alginate/chitosan films Juliano et al., 2008
Povidone iodine Alginate beads and films Liakos et al., 2013
Pomegranate extract Alginate microparticles Endo et al., 2012
Lactoferrin Alginate tablets Kuipers et al., 2002
Silver Alginate as a stabilizer silver
nanoparticles
Kubyshkin et al., 2016
Cellulose/sodium alginate films Shao et al., 2015
encapsulation efficiency of 80% for treatment of Candida
vaginitis. After ex vivo permeation studies through porcine
vaginal mucosa, determination of the amount of nystatin
retained and antifungal activity assays, the authors inferred that
the developed microparticulate system was efficacious against
C. albicans without systemic absorption of toxic concentrations
of the drug (Martín-Villena et al., 2013). More specifically,
the formulation was able to adhere to the vaginal mucosa
showing potential for safe treatment of localized infection.
Nystatin release from microcapsules followed a concentration
gradient pattern based on the first Fick’s law (release rate
constant: 1.60 h−1) offering sustained release (Martín-Villena
et al., 2013). Moreover, nystatin-loaded microparticles exhibited
a clear inhibition effect on the C. albicans growth (Martín-Villena
et al., 2013).
Alginate microspheres containing nystatin demonstrated
ability to control Candida infection in the oral cavity of pigs
without causing damage to the oral tissue and systemic nystatin
absorption (Martín et al., 2015). Another study for treatment
of oral candidiasis showed an improved nystatin effectiveness
using beads, micro- and nanoparticles of alginate incorporated
in toothpaste instead of free drug in suspension form (Reis et al.,
2015). This study demonstrated that microparticles were the most
suitable particulate system of nystatin showing the slowest release
(complete release within 3 h for beads, 24 h for nanoparticles,
and 48 h for microparticles), the highest inhibitory effect on
C. albicans (MIC value of 13.5 µg/mL for beads, 38 µg/mL for
nanoparticles, and 5.21 µg/mL for microparticles) and a high
antifungal efficiency over time (1 year of evaluation) (Reis et al.,
2015).
ALGINATE-BASED DELIVERY SYSTEMS
FOR NON-CONVENTIONAL
ANTIFUNGALS
Alginate formulations have been used as delivery systems for
other molecules with antifungal activity potential, such as
essential oils, antiseptics, and others (Table 2).
Turmeric oil from the rhizome of Curcuma longa is an
example of an essential oil encapsulated in alginate-based
carriers. Turmeric oil is widely used as a food additive, condiment
and household medicine in Southern Asia, and presents several
pharmacological properties as an antibacterial, an antifungal, an
antioxidant, an antimutagenic, and a repellent (Lertsutthiwong
et al., 2008). Lertsutthiwong et al. (2008) encapsulated this oil
in alginate nanocapsules, while Lertsutthiwong and Rojsitthisak
(2011) produced chitosan-alginate nanocapsules containing
turmeric oil. Chitosan-alginate nanocapsules increased the skin
permeation of turmeric oil compared with an ethanolic solution
(Lertsutthiwong and Rojsitthisak, 2011), representing a new
approach for topical delivery and treatment of cutaneous
infections (Lertsutthiwong and Rojsitthisak, 2011). These studies
also demonstrated that alginate is an effective biopolymer for
encapsulation of a volatile essential oil, producing nanocarriers
with long-term physical stability (120 days) when stored at 4◦C.
Hosseini et al. (2013) encapsulated Satureja hortensis essential
oil (known for its antimicrobial and antioxidant activity) in
alginate microparticles, and concluded that these microparticles
could be used for antioxidant and antimicrobial purposes with
controlled release properties in the food and nutraceuticals
industries. Other essential oils, such as elicriso italic, chamomile
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blue, cinnamon, lavender, tea tree, peppermint, eucalyptus,
lemongrass, and lemon were dispersed in sodium alginate films
and presented remarkable antibacterial and antifungal activities
(Liakos et al., 2014). These alginate films enriched with essential
oils should find multiple applications, including as disposable
wound dressings, in food packaging, medical device protection
and disinfection, and indoor air quality improvement materials
(Liakos et al., 2014).
Soliman et al. (2013) encapsulated clove, thyme and cinnamon
oils in alginate microspheres in order to achieve their optimal
antifungal activity against two of mycotoxigenic fungi species,
Aspergillus niger and Fusarium verticillioides, and prevent fungal
contamination in stored grains. These microspheres showed
antifungal activity in addition to increasing the storage time of
oil with antifungal activity for up to 8 days, while the free oil lost
activity within 2 days. Thus, the main advantage of encapsulation
was to reduce the rate of evaporation of these essential oils
prolonging antifungal activity (Soliman et al., 2013).
Plant extracts have also been incorporated in alginate-based
nanocarriers. The anise crude extracts and active compounds
manifest antimicrobial, antioxidant, insecticidal, analgesic,
sedative, and convulsive activities (Wang et al., 2011). Anise-
based bioadhesive alginate gels for vaginal application showed
antibacterial activity, and no effect against Candida species
was observed (Gafit˛anu et al., 2016). Alginate microparticles
containing pomegranate extract (Punica granatum) with
encapsulation efficiency of 81.9% (Endo et al., 2012) displayed
antifungal activity against C. albicans (minimum inhibitory
concentration of 3.9 µg/ml), with the advantage of providing
controlled extract release to achieve the desired therapeutic effect
against oral fungal infection caused by C. albicans (Endo et al.,
2012).
Sodium alginate tablets containing lactoferrin, a potential
antifungal candidate for candidiasis treatment, displayed release-
controlling and mucoadhesive properties (Kuipers et al., 2002). In
vitro microbiological studies demonstrated that the formulation
had the same antifungal properties as the free lactoferrin against
several clinical isolates of C. albicans and Candida glabrata
(Kuipers et al., 2002). The tablets (250 mg lactoferrin) on oral
mucosa of human volunteers were able to keep the lactoferrin
concentration in the saliva for at least 2 h, suggesting that they
might improve the therapeutic efficacy of lactoferrin in oral
candidiasis treatment (Kuipers et al., 2002).
Research showed that the use of sodium alginate as a
stabilizer provided a highly stable solution of silver nanoparticles
(nanosilver) that has significant antibacterial and antifungal
activity. The nanosilver aqueous solution at concentrations
of 0.0005–0.005% with sodium alginate completely inhibited
C. albicans viability within 24 h (Kubyshkin et al., 2016).
Shao et al. (2015) developed silver sulfadiazine-loaded
cellulose/sodium alginate films and observed that these
films had excellent antibacterial performances on E. coli and
S. aureus and antifungal activity on C. albicans. They also showed
good biocompatibility and accepted cytotoxicity (less than 20%
using 0.1% of silver sulfadiazine). The authors suggested that
these films containing silver sulfadiazine could be a potential
antimicrobial for use in wound dressings.
Antiseptics have also been incorporated in alginate carriers
for controlled release (Juliano et al., 2008; Liakos et al., 2013).
Films of sodium alginate or sodium alginate/chitosan were
well tolerated, and able to sustain the release of chlorhexidine
diacetate, providing active concentrations against C. albicans
for prolonged periods of time (approximately 3 h) on the
buccal mucosa of human volunteers, which is in agreement with
results showing in vitro mucoadhesion (Juliano et al., 2008).
Another antiseptic incorporated in alginate beads and films
was povidone iodine (PVPI) (Liakos et al., 2013). Controlled
release of PVPI was possible when the composite films and
beads were brought into direct contact with aqueous media,
maintaining the bactericidal and fungicidal properties. This
characteristic is highly desired in clinical applications to avoid
toxic doses of PVPI (Liakos et al., 2013). A wide variety of
applications of these systems are envisioned, such as wound
dressings, hygienic and protective packaging films for medical
devices, and polymer beads as water disinfectants (Liakos et al.,
2013).
CONCLUDING REMARKS
Alginate is a natural polymer widely used for obtainment of
drug delivery systems due to its non-toxicity, biodegradability,
biocompatibility, low cost, mucoadhesive, and non-immuno-
genic properties, in addition to the availability of simple
protocols for production of these systems. In spite of the
popularity of alginate-based carriers in the drug delivery field,
few studies have been conducted with antifungals, mostly
dealing with azoles and polyenes. Thus, there is a gap when
it comes to the advantages and limitations of alginate-based
carriers for other types of antifungal agents. To the best of
our knowledge, this review is the first to directly focus on
alginate carriers for antifungal drugs. Based on the studies
discussed here, alginate-based antifungal delivery systems have
shown great potential in the treatment of fungal infections,
providing modified release, and decreasing administration
frequency, toxicity and the dose necessary for antifungal
efficacy. Therefore, the use of alginate-based carriers represents
a promising approach for delivery of antifungal agents to
improve the treatment protocols for cutaneous and systemic
mycosis.
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